Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stimulant drugs are second only to cannabis as the most widely used class of illicit drug globally, accounting for 68 million past-year consumers. Dependence on amphetamines (AMPH) or methamphetamine (MA) is a growing global concern. Yet, there is no established pharmacotherapy for AMPH/MA dependence. A comprehensive assessment of the research literature on pharmacotherapy for AMPH/MA dependence may inform treatment guidelines and future research directions. METHODS: We systematically reviewed the peer-reviewed literature via the electronic databases PubMed, EMBASE, CINAHL and SCOPUS for randomised controlled trials reported in the English language examining a pharmacological treatment for AMPH/MA dependence or use disorder. We included all studies published to 19 June 2019. The selected studies were evaluated for design; methodology; inclusion and exclusion criteria; sample size; pharmacological and (if included) psychosocial interventions; length of follow-up and follow-up schedules; outcome variables and measures; results; overall conclusions and risk of bias. Outcome measures were any reported impact of treatment related to AMPH/MA use. RESULTS: Our search returned 43 studies that met our criteria, collectively enrolling 4065 participants and reporting on 23 individual pharmacotherapies, alone or in combination. Disparate outcomes and measures (n = 55 for the primary outcomes) across studies did not allow for meta-analyses. Some studies demonstrated mixed or weak positive signals (often in defined populations, e.g. men who have sex with men), with some variation in efficacy signals dependent on baseline frequency of AMPH/MA use. The most consistent positive findings have been demonstrated with stimulant agonist treatment (dexamphetamine and methylphenidate), naltrexone and topiramate. Less consistent benefits have been shown with the antidepressants bupropion and mirtazapine, the glutamatergic agent riluzole and the corticotropin releasing factor (CRF-1) antagonist pexacerfont; whilst in general, antidepressant medications (e.g. selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs]) have not been effective in reducing AMPH/MA use. CONCLUSIONS: No pharmacotherapy yielded convincing results for the treatment of AMPH/MA dependence; mostly studies were underpowered and had low treatment completion rates. However, there were positive signals from several agents that warrant further investigation in larger scale studies; agonist therapies show promise. Common outcome measures should include change in use days. Future research must address the heterogeneity of AMPH/MA dependence (e.g. coexisting conditions, severity of disorder, differences between MA and AMPH dependence) and the role of psychosocial intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bupropion has been shown to reduce nicotine/tobacco use in patients who smoke cigarettes or use other nicotine/tobacco products.109”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the current body of evidence supporting prescription stimulants for treating stimulant use disorders remains inconclusive [58,66,67,68,69].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Demand for treatment is increasing globally [4]; however, there are currently no approved pharmacotherapies, despite extensive research investigating potential candidates [6][7][8].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are no robustly effective pharmacotherapies available (6)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“which is encouraging, given the dropout rates of around 40% in prior studies of MAUD treatments [8].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [8]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
International Statistical Classification of Diseases and Related Health Problems
Eisfeld, J. (2014) · TSQ: Transgender Studies Quarterly · doi:10.1215/23289252-2399740 · Cited by 3,570
White, J. M. L., Kita, M., Krpelanová, E., Alsokhn, C., Costa, M. L., Fibbe, W., Gaebel, W., Reed, G. M., Lokuhetty, D., Woolf, A., et al. (2026) · Bulletin of the World Health Organization · doi:10.2471/blt.25.294650 · Cited by 832
Research works printed but not linked: 5
- World Health Organization. ICD-11: International classification of diseases for mortality and morbidity statistics: 11th rev. Geneva: World Health Organisation; 2018.
- United Nations Office on Drugs and Crime. Treatment of stimulant use disorder: Current practices and promising perspectives. Vienna: United Nations Office on Drugs and Crime; 2019.
- Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. www.covidence.org.
- Center for Behavioral Health Statistics and Quality. Results from the 2016 national survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2017.
- Australian Institute of Health and Welfare. National drug strategy household survey 2016: detailed findings. Canberra: Australian Institute of Health and Welfare; 2017.
Cited by
Bupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Berríos‐Cárcamo, P., Quezada, M., Quintanilla, M. E., Morales, P., Ezquer, M., Herrera‐Marschitz, M., Israel, Y., & Ezquer, F. E. (2020) · Antioxidants · doi:10.3390/antiox9090830 · Cited by 121
“Treatments against the abuse of other drugs have been shown to be ineffective [11] or inconclusive [12].”
BackgroundPharmacotherapeutic strategies for treating cocaine use disorder—what do we have to offer?
Brandt, L., Chao, T. W.-C., Comer, S. D., & LEVIN, F. R. (2020) · Addiction · doi:10.1111/add.15242 · Cited by 94
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2022.2134739 · Cited by 86
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Metadata
- Authors
- Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N.
- Affiliations
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- The University of Sydney (AU)
- Corresponding author
- Siefried, Krista J.
- Venue
- CNS Drugs
- Published
- 2020-03-17
- Volume
- 34
- Issue
- 4
- Pages
- 337-365
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC7125061
- OpenAlex
- W3010839704
- Semantic Scholar
- c6abc4f20be8eb30ef85f0d999db84d5387a80c2
- Cited by
- 194
- References
- 84
- Citations by year
- 2026: 17 · 2025: 42 · 2024: 32 · 2023: 29 · 2022: 38 · 2021: 31 · 2020: 5
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- Department of Health, Australian Government
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- methamphetamine dependence, amphetamine dependence, pharmacotherapy, d-amphetamine, methylphenidate, naltrexone, topiramate, bupropion, mirtazapine, riluzole, antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, men who have sex with men
- MeSH terms
- Amphetamine, Central Nervous System Stimulants, Animals, Humans, Methamphetamine, Substance-Related Disorders, Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. https://app.cochat.ai/papers/10.1007/s40263-020-00711-x
- The paper
- Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020). Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. CNS Drugs. https://doi.org/10.1007/s40263-020-00711-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
